UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

European heart journal, 2008-07, Vol.29 (14), p.1761-1771

2008

Volltextzugriff (PDF)

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

British journal of dermatology (1951), 2016-11, Vol.175 (5), p.902-911

2016

Volltextzugriff (PDF)

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

The Lancet (British edition), 2017-07, Vol.390 (10093), p.457-468

2017

Volltextzugriff (PDF)

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

Journal of the American Academy of Dermatology, 2017-01, Vol.76 (1), p.22-28

2017

Volltextzugriff (PDF)

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.1554-1573.e12

2020

Volltextzugriff (PDF)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Arthritis research & therapy, 2019-04, Vol.21 (1), p.89-18, Article 89

2019

Volltextzugriff (PDF)

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

The Lancet infectious diseases, 2015-10, Vol.15 (10), p.1167-1174

2015

Volltextzugriff (PDF)

CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant

Journal of neuroendocrinology, 2008-05, Vol.20 (s1), p.139-146

Scheen, A. J.

2008

Volltextzugriff (PDF)

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

The New England journal of medicine, 2019-06, Vol.380 (25), p.2406-2417

2019

Volltextzugriff (PDF)

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial

Annals of internal medicine, 2013-08, Vol.159 (4), p.253

2013

Volltextzugriff (PDF)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2014-10, Vol.66 (10), p.2675-2684

2014

Volltextzugriff (PDF)

Histamine Receptor H1-mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.875-887.e9

2016

Volltextzugriff (PDF)

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Gastroenterology (New York, N.Y. 1943), 2021-11, Vol.161 (5), p.1475-1486

2021

Volltextzugriff (PDF)

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Volltextzugriff (PDF)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.733-742

2019

Volltextzugriff (PDF)

A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

The New England journal of medicine, 2020-01, Vol.382 (3), p.222-232

2020

Volltextzugriff (PDF)

Tofacitinib for the treatment of alopecia areata and variants in adolescents

Journal of the American Academy of Dermatology, 2017-01, Vol.76 (1), p.29-32

2017

Volltextzugriff (PDF)

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Annals of the rheumatic diseases, 2022-06, Vol.81 (6), p.798-804

2022

Volltextzugriff (PDF)

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial

Lancet neurology, 2013-11, Vol.12 (11), p.1068-1075

2013

Volltextzugriff (PDF)

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Clinical gastroenterology and hepatology, 2022-03, Vol.20 (3), p.591-601.e8

2022

Volltextzugriff (PDF)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.464-478

2022

Volltextzugriff (PDF)

Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review

Journal of rheumatology, 2020-02, Vol.47 (2), p.176-187

2020

Volltextzugriff (PDF)

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

The New England journal of medicine, 2012-03, Vol.366 (10), p.893-903

2012

Volltextzugriff (PDF)

1 – 25 von 822

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(763)
Mit Volltextzugriff
(632)

Publikationsform

Artikel
(822)

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(814)
Science & Technology
(707)
Life Sciences & Biomedicine
(700)
Piperidines - Adverse Effects
(608)
Female
(554)
Male
(524)
Piperidines - Therapeutic Use
(471)
Middle Aged
(451)
Adult
(380)
Aged
(344)
Piperidines - Administration & Dosage
(343)
Double-Blind Method
(208)
Biological And Medical Sciences
(205)
Medical Sciences
(202)
Aged, 80 And Over
(142)
Pyrimidines - Adverse Effects
(141)
Indans - Adverse Effects
(121)
Dose-Response Relationship, Drug
(120)
Neurosciences & Neurology
(117)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

Histamine Receptor H1-mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

Tofacitinib for the treatment of alopecia areata and variants in adolescents

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Aktive Filter

Suchergebnisse filtern